Conditions: Malignant Melanoma
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 24
Healthy volunteers: no

Brief summary:
This open-label study will assess the safety and efficacy of RO5185426 in previously treated metastatic melanoma patients with brain metastases. Patients will receive RO5185426 at a dose of 960 mg twice daily orally until disease progression or unacceptable toxicity occurs.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: RO5185426
Intervention descriptions: intervention 1: 960 mg b.i.d. orally

Protocol document: